Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Status:
Not yet recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of chidamide combined with
sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Harbin Medical University The First Affiliated Hospital of Xiamen University